597k€ were obtained thanks to the support of a various range of investors including societies such as INSAVALOR, EZUS, AVNIR, Nano-H, Chematech and few individuals.
This capital raise is a major financial progress and it will help to create added value to the one already existing after one year of existence. Especially, NH TherAguix will be able to reinforce its clinical strategy by pursuing the development of its drug candidate AGuIX®, including preparation of phase 2 clinical trials, broadening of indications and production of other batches of drug. We look forward to deploying these funds successfully.
To all the investors, your support means so much for all of us. On behalf of the team, I wish to warmly thank you all for your continued confidence during the raising process.